Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 18/20 | 0.58 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | DRD3 | P35462 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 6/20 | 0.46 |
| ▸ | HTR1A | P08908 | 4/20 | 0.46 |
| ▸ | HTR7 | P34969 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 4/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201506 | 0.89 | HTR6 (0.47) | HTR6DRD2DRD3HTR2AHTR1A | |
| SCHEMBL5202025 | 0.86 | HTR6 (0.67) | HTR6DRD2DRD3HTR2AHTR1A | |
| SCHEMBL14445203 | 0.84 | HTR6 (0.55) | HTR6DRD2DRD3HTR2AHTR1A | |
| SCHEMBL5201187 | 0.81 | HTR6 (0.53) | HTR6DRD2HTR2AHTR1AHTR7 | |
| SCHEMBL5201209 | 0.81 | HTR6 (0.78) | HTR6DRD2DRD3HTR2AHTR1A | |
| SCHEMBL4675283 | 0.81 | HTR6 (0.76) | HTR6DRD2DRD3HTR2AHTR1A | |
| SCHEMBL5201291 | 0.79 | HTR6 (0.48) | HTR6DRD3HTR2AHTR2CHTR2B | |
| SCHEMBL14395298 | 0.78 | HTR6 (0.62) | HTR6DRD2HTR2AHTR1AHTR7 | |
| SCHEMBL5202731 | 0.75 | HTR6 (0.62) | HTR6DRD2HTR2AHTR1AHTR7 | |
| SCHEMBL5203293 | 0.74 | HTR6 (0.50) | HTR6DRD2DRD3HTR2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1587788-B9 | 2,7-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-10-24 | — | — | EP | claimed |
| US-7247651-B2 | 2,7-substituted indoles | ROCHE PALO ALTO LLC (US) | 2007-07-24 | — | — | US | claimed |
| EP-1587788-B1 | 2,7-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-05-16 | — | — | EP | claimed |
| CN-1314669-C | 2,7-substituted indoles and their use as 5-HT6 modulators | HOFFMANN LA ROCHE (CH) | 2007-05-09 | — | — | CN | claimed |
| EP-1587788-A1 | 2,7-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-26 | — | — | EP | claimed |
| CN-1681782-A | 2, 7-substituted indoles and their use as 5-HT 6 modulators | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | CN | claimed |
| WO-2004026830-A1 | 2,7-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | claimed |
| EP-1587788-B9 | 2,7-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-10-24 | — | — | EP | disclosed |
| EP-1587788-B9 | 2,7-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-10-24 | — | — | EP | disclosed |
| US-7247651-B2 | 2,7-substituted indoles | ROCHE PALO ALTO LLC (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247651-B2 | 2,7-substituted indoles | ROCHE PALO ALTO LLC (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247651-B2 | 2,7-substituted indoles | ROCHE PALO ALTO LLC (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1587788-B1 | 2,7-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-05-16 | — | — | EP | disclosed |
| EP-1587788-B1 | 2,7-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-05-16 | — | — | EP | disclosed |
| CN-1314669-C | 2,7-substituted indoles and their use as 5-HT6 modulators | HOFFMANN LA ROCHE (CH) | 2007-05-09 | — | — | CN | disclosed |
| EP-1587788-A1 | 2,7-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-26 | — | — | EP | disclosed |
| CN-1681782-A | 2, 7-substituted indoles and their use as 5-HT 6 modulators | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | CN | disclosed |
| US-20040063724-A1 | Neurotransmitter 5-hydroxytryptamine-6 (5-HT6) antagonists | ROCHE PALO ALTO LLC | 2004-04-01 | — | — | US | disclosed |
| WO-2004026830-A1 | 2,7-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063724-A1 | Neurotransmitter 5-hydroxytryptamine-6 (5-HT6) antagonists | HTR6, HTR5A, HTR1A | HTR6 1/4885DRD2 59/4885DRD3 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.